Quantification of topotecan by liquid chromatography-mass spectrometry (LC-MS). Application to intestinal transport using rat everted gut sacs

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 878, Issue 7-8, 2010, Pages 645-652

  Arellano, Cécile ^c   Gandia, Peggy ^b,c   Bettuing, Laure ^a   Woodley, John ^a   Chatelut, Etienne ^c  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Institut Federatif de Biologie   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Everted gut sacs; Keto enol tautomerism; LC MS; Ondansetron; Topotecan

Indexed keywords

ANTICANCER DRUG; BIOLOGICAL MEDIA; GUT SAC; IN-VITRO; INTESTINAL ABSORPTION; KETO-ENOL TAUTOMERISM; LC-MS METHODS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIQUID-LIQUID EXTRACTION; P-GLYCOPROTEIN; POTENTIAL DRUG; TOPOTECAN;

CHROMATOGRAPHIC ANALYSIS; COMPLEXATION; GLYCOPROTEINS; LIQUID CHROMATOGRAPHY; LIQUIDS; MASS SPECTROMETRY; SOLVENT EXTRACTION;

DRUG INTERACTIONS;

GLYCOPROTEIN P; LACTONE; ONDANSETRON; TOPOTECAN;

ACCURACY; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG TISSUE LEVEL; DRUG UPTAKE; ELECTROSPRAY MASS SPECTROMETRY; INTESTINE ABSORPTION; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; NONHUMAN; PH MEASUREMENT; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, LIQUID; DRUG INTERACTIONS; DUODENUM; HYDROGEN-ION CONCENTRATION; LEAST-SQUARES ANALYSIS; MALE; MASS SPECTROMETRY; MODELS, BIOLOGICAL; ONDANSETRON; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOPOTECAN;

RATTUS;

EID: 76549084520     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2010.01.019     Document Type: Article

References (35)

1. Li H., Jin H.E., Kim W., Han Y.H., Kim D.D., Chung S.J., and Shim C.K. Pharm. Res. 25 (2008) 2601
2. Schinkel A.H., Wagenaar E., Mol C.A., and van Deemster L. J. Clin. Invest. 97 (1996) 2517
3. Endres C.J., Hsiao P., Chung F.S., and Unadkat J.D. Eur. J. Pharm. 27 (2006) 501
4. Scott J.A., Wood M., and Flood P. Anest. Analg. 103 (2006) 742
5. Balayssac D., Authier N., Cayre A., and Coudore F. Toxicol. Lett. 156 (2005) 319
6. Rosing H., Herben V.M., van Gortel-van Zomeren D.M., Hop E., Kettenes-van den Bosch J.J., ten Bokkel Huinink W.W., and Beijnen J.H. Cancer Chemother. Pharmacol. 39 (1997) 498
7. de Vries N.A., Ouwehand M., Buckle T., Beijnen J.H., and van Tellingen O. Biomed. Chromatogr. 21 (2007) 1191
8. Bai F., Kirstein M.N., Hanna S.K., Iacono L.C., Johnston B., and Stewart C.F. J. Chromatogr. B 784 (2003) 225
9. Vali A.M., Shafaghi B., and Dadashzadeh S. J. Chromatogr. B 818 (2005) 205
10. Bansal T., Singh M., Mishra G., Talegaonkar S., Khar R.K., Jaggi M., and Mukherjee R. J. Chromatogr. B 859 (2007) 261
11. Srinivas N.R. Biomed. Chromatogr. 23 (2009) 447
12. Arellano C., Philibert C., Lacombe O., Woodley J., and Houin G. J. Chromatogr. B 807 (2004) 263
13. Arellano C., Philibert C., Dane a Yakan E.N., Vachoux C., Lacombe O., Woodley J., and Houin G. J. Chromatogr. B 819 (2005) 105
14. Arellano C., Philibert C., Vachoux C., Woodley J., and Houin G. J. Chromatogr. B 829 (2005) 50
15. Arellano C., Philibert C., Vachoux C., Woodley J., and Houin G. J. Pharm. Pharmaceut. Sci. 10 (2007) 26
16. Bardin S., Guo W., Johnson J.L., Khan S., Ahmad A., Duggan J.X., Ayoub J., and Ahmad I. J. Chromatogr. A 1073 (2005) 249
17. Matuszewski B.K., Constanzer M.L., and Chavez-Eng C.M. Anal. Chem. 70 (1998) 882
18. Buhrman D.L., Price P.I., and Rudewicz P.J. J. Am. Soc. Mass Spectrom. 7 (1996) 1099
19. Strel'tsov S.A., Grokhovskii S.L., Kudelina I.A., Oleinikov V.A., and Zhuze A.L. Mol. Biol. 35 (2001) 365
20. Sanna N., Chillemi G., Grandi A., Castelli S., Desideri A., and Barone V. J. Am. Chem. Soc. 127 (2005) 15429
21. Cherlet M., De Backer P., and Croubels S. J. Chromatogr. A 1133 (2006) 135
22. Cherlet M., Croubels S., and De Backer P. J. Chromatogr. A 1102 (2006) 116
23. Blanchflower W.J., McCracken R.J., Haggan A.S., and Kennedy D.G. J. Chromatogr. B 692 (1997) 351
24. FDA, in: Food and Drug Administration, Rockville, MD, 2002.
25. Tamai I., Saheki A., Saitoh R., Sai Y., Yamada I., and Tsuji A. J. Pharmacol. Exp. Ther. 283 (1997) 108
26. Jeong E.J., Liu X., Jia X., Chen J., and Hu M. Curr. Drug Metab. 6 (2005) 455
27. de Vries N.A., Zhao J., Kroon E., Buckle T., Beijnen J.H., and van Tellingen O. Clin. Cancer Res. 13 (2007) 6440
28. Barthe L., Bessouet M., Woodley J.F., and Houin G. Int. J. Pharm. 173 (1998) 255
29. Cornaire G., Woodley J.F., Herman P., Cloarec A., Arrellano C., and Houin G. Int. J. Pharm. 278 (2004) 119
30. Kuppens I.E., Witteveen E.O., Jewell R.C., Radema S.A., Paul E.M., Mangum S.G., Beijnen J.H., Voest E.E., and Schellens J.H. Clin. Cancer Res. 13 (2007) 3276
31. Muenster U., Grieshop B., Ickenroth K., and Gnoth M.J. Pharm. Res. 25 (2008) 2320
32. Jonker J.W., Smit J.W., Brinkhuis R.F., Maliepaard M., Beijnen J.H., Schellens J.H., and Schinkel A.H. J. Natl. Cancer Inst. 92 (2000) 1651
33. Breedveld P., Beijnen J.H., and Schellens J.H. Trends Pharm. Sci. 27 (2006) 17
34. Oostendorp R.L., Beijnen J.H., and Schellens J.H. Cancer Treat. Rev. 35 (2009) 137
35. Kruijtzer C.M., Beijnen J.H., Rosing H., ten Bokkel Huinink W.W., Schot M., Jewell R.C., Paul E.M., and Schellens J.H. J. Clin. Oncol. 20 (2002) 2943